Matt Hims Email & Phone Number

Boston, Ma, Us

Cambridge, Ma, Us

Cambridge, Massachusetts, United States

Lead team of research scientist, optimizing a sequencing-based component of a Multi-Cancer Early Detection (MCED) liquid biopsy assay.Served on the MCED assay leadership team, offering critical direction and strategic insight for product development initiatives.Directed efforts in molecular biology to refine workflow and reagents, aiming to decrease assay expenses, enhance efficiency, and boost assay sensitivity, succeeding in developing a component for Exact Sciences’ MCED assay that enabled highly sensitive and precise mutation detection.

Cambridge, Massachusetts, United States

Lab Head and Research Investigator in the Next Generation Diagnostic (NGDx) team supporting the Novartis oncology research pipeline.Jointly led a state-of-the-art sequencing laboratory, providing advanced genomic technologies and delivering clinical data for Novartis oncology studies.Directed the innovative technology team in evaluating and deploying novel NGS assays. Validated assays encompassed hybrid capture and amplicon panels, and cfDNA, and single-cell RNA sequencing methods. Under development were multi-omic single-cell and spatial transcriptomics techniques.

Cambridge, Massachusetts, United States

Developed and validated second iteration of NGDx cfDNA Oncology assay, incorporating single and duplex sequencing capabilities, and error pool of normal suppression strategies.Project managed laboratory workflows, samples and procedures across various clinical and assay development initiatives, facilitating collaboration between laboratory and data science teams.Developed and maintained an internal Quality Management System tailored for the management of clinical samples, process oversight, handling of CAPA, and control of documentation

Cambridge, Ma

Research Scientist in Novartis Next Generation Diagnostic Group.Contributed to the building and establishment the NGDx group and laboratory as a new research entity within Novartis.Developed and validated internal cfDNA liquid biopsy assay for use in Novartis Oncology trials.

Cambridge, England, United Kingdom

Research and development scientist at a fast-paced, industry leading Next Generation Sequencing technology company.Designed and executed research experiments to support both sequencing technology improvements and new product innovations focused on NGS library preparation.Served as the technical lead for numerous product development initiatives, significantly contributing to the design, creation, and launch of two Illumina products: the Mate Pair Sample Prep Kit and the Nextera Mate Pair Sample Prep Kit.Advised on technology strategy and feasibility as part of the Peer Technology Review Committee.Filed a US patent application (US# 20090093378) and submitted multiple internal invention disclosures.Wrote and edited technical documents, commercial protocols, and user guides.

Research and development scientist at pioneering and industry changing Next Generation Technology company. ( Soon to be acquired by Illumina).Contributed to the development of Library Construction protocols; mate-pair and paired-end sequencing method.

Boston, Ma

Continued investigations into the molecular mechanism of the human neuro-degenerative disease Familial Dysautonomia (FD), carrying out basic research into the causative splicing defect and mechanism of action of a potential therapeutic agent.

Investigations into the molecular mechanism of the human neuro-degenerative disease Familial Dysautonomia (FD), carrying out basic research into the causative splicing defect and mechanism of action of a potential therapeutic agent.

Leeds, England

Gained experience and grounding in molecular biology and human genetics. Thesis title: Molecular Genetics of Retinal Degenerations.

York, United Kingdom

Phd, Human Genetics And Molecular Biology

Bsc, Genetics